J Cancer 2017; 8(8):1355-1361. doi:10.7150/jca.18014
Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer
1. Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China;
2. Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China;
3. First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China;
4. Department of Colorectal Surgery, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China;
5. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
* These authors contributed equally to the writing of this article.
Li S, Xie L, He L, Fan Z, Xu J, Xu K, Zhu L, Ma G, Du M, Chu H, Zhang Z, Ni M, Wang M. Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer. J Cancer 2017; 8(8):1355-1361. doi:10.7150/jca.18014. Available from https://www.jcancer.org/v08p1355.htm
Objective Mesothelin is a cell surface protein and overexpressed in many cancers. However, the potential value of mesothelin as plasma biomarker in colorectal cancer has not been explored. The purpose of this study was to identify whether plasma mesothelin is a suitable diagnostic and prognostic biomarker for colorectal cancer.
Methods We performed a two-stage case-control study to evaluate plasma mesothelin levels in colorectal cancer using enzyme-linked immunosorbent assay (ELISA). Preoperative and postoperative plasma were collected to examine the level changes influenced by surgery. Receiver operating characteristic (ROC) curves were applied to identify the diagnostic value of plasma mesothelin. We also conducted univariate Kaplan-Meier survival analysis and Cox regression analysis of patients with survival information.
Results We found that the plasma mesothelin levels in colorectal cancer patients were significantly higher than that in the controls (P < 0.001) with an AUC value of 0.690 (95% CI = 0.625 to 0.752). Individuals with lower mesothelin level had a longer survival time (adjusted HR = 4.43, 95% CI = 1.93-10.15, P < 0.001). Furthermore, Patients had slightly decreased mesothelin levels in postoperative plasma than preoperative plasma, although the alteration was not statistically significant (P = 0.052).
Conclusion Our findings highlight the correlative relationship between plasma mesothelin levels and the presence and progression of colorectal cancer. Plasma mesothelin may be a potential diagnostic and, or prognostic biomarker for colorectal cancer.
Keywords: mesothelin, colorectal cancer, biomarker.